메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Yale-Trained Neuroscientist Unveils "Digital Sunshine" Device, Merging Ancient Eastern Wisdom with Modern Brain Science to Revolutionize Sleep

[ 메디채널 김갑성 기자 ] Panbrain Lume Offers a Drug-Free Path to Deeper Sleep and Faster Sleep Onset in Just 8 Minutes, Now Live on Kickstarter NEW HAVEN, Conn., Nov. 28, 2025 -- In a bold fusion of cutting-edge neuroscience and ancient Eastern wellness principles, Dr. Nailin Yao, a former Yale postdoctoral fellow in psychiatry, today announces the launch of Panbrain Lume. This revolutionary intranasal near-infrared (NIR) photobiomodulation device is designed to combat the global sleep crisis with a simple, 8-minute nightly routine. Backed by robust science, Panbrain Lume is clinically engin
- 김갑성 기자
- 2025-11-28 14:20
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in China targeting difficult-to-treat cancers. This approach represents a first-in-class "mark and kill" strategy, leveraging oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.
- 김갑성 기자
- 2025-11-28 13:00
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma

CHENGDU, China, Nov. 28, 2025 -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been published in the journal of Annals of Oncology (Impact Factor: 65.4). This study provides the first evidence of sac-TMT's potential significant clinical benefit for patients with advanced UC. This publication is based on the efficacy and safety results of cohort 9 of a phase II M
- 김갑성 기자
- 2025-11-28 12:32
Keep Your Respiratory Health Strong This Season With VARON Black Friday Offers

NEW YORK, Nov. 28, 2025 -- As the holiday season approaches, respiratory health becomes a top priority for individuals living with chronic conditions such as COPD, sleep apnea, or other lung diseases. VARON, a leading provider of portable oxygen concentrators and home oxygen concentrators, is officially launching its Black Friday 2025 sale from November 28 through November 30, offering unprecedented sitewide savings, featured deals, and exclusive bundle offers designed to support health and mobility. Comprehensive Savings and Holiday Incentives This year, V
- 김갑성 기자
- 2025-11-28 06:09
Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market

SHANGHAI, Nov. 27, 2025 -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and South Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the Korean market, and global market expansion. This partnership leverages Sanyou Bio's globally leading AI-STAL drug discovery platform and FatiAbGen's deep local presence in South Korea to drive synergistic growth across Korea, Europe, and beyond — empowering biotech innovators worldwide. The
- 김갑성 기자
- 2025-11-27 22:00
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

BEIJING, Nov. 27, 2025 -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore its potential to maintain the achieved weight loss and improved long-term adherence. This phase 3 study (Chinadrugtrials.org.c
- 김갑성 기자
- 2025-11-27 16:57
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma

SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, today announced that the Biologics License Application (BLA) for its independently developed fully human anti-BCMA CAR-T therapy Fucaso (Equecabtagene Autoleucel) has been approved by the Hong Kong Department of Health. The therapy is indicated for adult patients with rel
- 김갑성 기자
- 2025-11-27 13:44
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology

YONGIN, South Korea, Nov. 27, 2025 -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of Gastroenterology(AJG). GC Genome applied its proprietary AI-based fragmentomics technology, used in its MCED test, ai-CANCERCH. This study demonstrates the potential for a convenient, alternative to colonoscopy and fecal based screening methods, while enabling early detection of colorectal cancer and advanced adenomas
- 김갑성 기자
- 2025-11-27 13:00
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation

[ 메디채널 김갑성 기자 ] New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 27, 2025 -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights for research and development (R&D), manufa
- 김갑성 기자
- 2025-11-27 10:39
Patronus Biotech receives grant to evaluate a novel malaria vaccine and adjuvant to support affordable access and use in global health

SINGAPORE, Nov. 27, 2025 -- Patronus Biotech today announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant program to support affordable access and use in global health. The funding will enable the evaluation of an innovative U-VLP® vaccine candidate, LYB014, which targets multiple stages of the most deadly form of malaria parasite's life cycle; as well as a new, low cost, highly pure adjuvant manufactured from synthetic components. Malaria remains one of the world's most devastating infectious diseases, with an es
- 김갑성 기자
- 2025-11-27 09:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분